JP2019013220A - Food composition aiming at sodium excretion - Google Patents
Food composition aiming at sodium excretion Download PDFInfo
- Publication number
- JP2019013220A JP2019013220A JP2018125691A JP2018125691A JP2019013220A JP 2019013220 A JP2019013220 A JP 2019013220A JP 2018125691 A JP2018125691 A JP 2018125691A JP 2018125691 A JP2018125691 A JP 2018125691A JP 2019013220 A JP2019013220 A JP 2019013220A
- Authority
- JP
- Japan
- Prior art keywords
- sodium
- food composition
- salt
- alginate
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims abstract description 109
- 229910052708 sodium Inorganic materials 0.000 title claims abstract description 109
- 239000011734 sodium Substances 0.000 title claims abstract description 109
- 239000000203 mixture Substances 0.000 title claims abstract description 103
- 235000013305 food Nutrition 0.000 title claims abstract description 99
- 230000029142 excretion Effects 0.000 title abstract description 8
- -1 organic cation salt Chemical class 0.000 claims abstract description 77
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 64
- 229920000615 alginic acid Polymers 0.000 claims abstract description 64
- 229940072056 alginate Drugs 0.000 claims abstract description 39
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 claims abstract description 30
- 235000010407 ammonium alginate Nutrition 0.000 claims abstract description 29
- 239000000728 ammonium alginate Substances 0.000 claims abstract description 29
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000783 alginic acid Substances 0.000 claims abstract description 25
- 229960001126 alginic acid Drugs 0.000 claims abstract description 25
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 18
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 14
- 150000003863 ammonium salts Chemical class 0.000 claims abstract description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 42
- 229910052700 potassium Inorganic materials 0.000 claims description 41
- 239000011591 potassium Substances 0.000 claims description 41
- 239000000654 additive Substances 0.000 claims description 22
- 238000007599 discharging Methods 0.000 claims description 21
- 229910001411 inorganic cation Inorganic materials 0.000 claims description 21
- 229910052751 metal Inorganic materials 0.000 claims description 14
- 239000002184 metal Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 230000008085 renal dysfunction Effects 0.000 claims description 10
- 159000000007 calcium salts Chemical class 0.000 claims description 9
- 230000000996 additive effect Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 235000011194 food seasoning agent Nutrition 0.000 claims description 7
- 239000004278 EU approved seasoning Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- 159000000003 magnesium salts Chemical class 0.000 claims description 5
- 150000003751 zinc Chemical class 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 150000002505 iron Chemical class 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000008274 jelly Substances 0.000 claims description 4
- 239000003205 fragrance Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 abstract description 12
- 235000015424 sodium Nutrition 0.000 description 89
- 230000000694 effects Effects 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000001179 sorption measurement Methods 0.000 description 17
- 239000000284 extract Substances 0.000 description 16
- 235000013361 beverage Nutrition 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 235000010410 calcium alginate Nutrition 0.000 description 11
- 239000000648 calcium alginate Substances 0.000 description 11
- 229960002681 calcium alginate Drugs 0.000 description 11
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 11
- 230000036514 plasma sodium concentration Effects 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 206010062237 Renal impairment Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 239000004166 Lanolin Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 235000019388 lanolin Nutrition 0.000 description 6
- 229940039717 lanolin Drugs 0.000 description 6
- 229910021645 metal ion Inorganic materials 0.000 description 6
- 231100000857 poor renal function Toxicity 0.000 description 6
- 101100352919 Caenorhabditis elegans ppm-2 gene Proteins 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 240000007817 Olea europaea Species 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000014659 low sodium diet Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000012176 shellac wax Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000000892 thaumatin Substances 0.000 description 2
- 235000010436 thaumatin Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- PBTPTBMYJPCXRQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O PBTPTBMYJPCXRQ-MGMRMFRLSA-N 0.000 description 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- OJFZYAQGMWSUID-QFIPXVFZSA-N (2s)-2-(4-chlorophenyl)-2-pyridin-3-yl-1-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethanone Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCN(C(=O)[C@@H](C=2C=CC(Cl)=CC=2)C=2C=NC=CC=2)CC1 OJFZYAQGMWSUID-QFIPXVFZSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- DFMMVLFMMAQXHZ-DOKBYWHISA-N 8'-apo-beta,psi-caroten-8'-al Chemical compound O=CC(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C DFMMVLFMMAQXHZ-DOKBYWHISA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 235000014722 Aralia cordata Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- FDKAAIFOPLCYAM-UHFFFAOYSA-M C(C(O)C)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[Ca+] Chemical compound C(C(O)C)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[Ca+] FDKAAIFOPLCYAM-UHFFFAOYSA-M 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001653 FEMA 3120 Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- VQENOYXMFIFHCY-UHFFFAOYSA-N Monoglyceride citrate Chemical compound OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O VQENOYXMFIFHCY-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061457 Solanum nigrum Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000004552 Yucca aloifolia Nutrition 0.000 description 1
- 235000012044 Yucca brevifolia Nutrition 0.000 description 1
- 235000017049 Yucca glauca Nutrition 0.000 description 1
- 240000005780 Yucca gloriosa Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JVOGSHDZLOJKKR-MXFMKSRJSA-I [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O Chemical compound [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O JVOGSHDZLOJKKR-MXFMKSRJSA-I 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 235000013735 beta-apo-8'-carotenal Nutrition 0.000 description 1
- 239000001652 beta-apo-8'-carotenal Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 239000002967 calcium-L-ascorbate Substances 0.000 description 1
- 235000005937 calcium-L-ascorbate Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000015120 cherry juice Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 108010010165 curculin Proteins 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 125000000422 delta-lactone group Chemical group 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 239000000182 glucono-delta-lactone Substances 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- 239000004306 orthophenyl phenol Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 150000008379 phenol ethers Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 235000013997 pineapple juice Nutrition 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 235000013995 raspberry juice Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 235000013948 strawberry juice Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940119463 sunflower seed extract Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229930185549 teaseedsaponin Natural products 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Jellies, Jams, And Syrups (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明は，ナトリウム排出を目的とした食品組成物に関する。さらに詳しく言うと本発明は，体内に摂取することにより，消化管内においてナトリウムを吸着し，体外への排泄を促進する食品組成物に関する。 The present invention relates to a food composition for sodium discharge. More specifically, the present invention relates to a food composition that adsorbs sodium in the digestive tract and promotes its excretion outside the body by ingestion into the body.
人工透析をはじめとして，腎機能に障害を持つ患者の多くは，非常に厳しい食事制限が課されている。特に食塩の過剰摂取は，健康に極めて悪い影響を及ぼすことから，基本的には無塩・減塩の食事となってしまう。結果として，患者の濃い味の食べ物に対する渇望は，健常者の想像を絶するものである。
このような事情から，体外への塩分排出を促進する組成物に関する技術が開示されている（特許文献１）。
Many patients with impaired renal function, including artificial dialysis, have very strict dietary restrictions. In particular, excessive intake of salt has a very bad effect on health, so it basically results in a salt-free and low-salt diet. As a result, the patient's craving for deep-flavored food is beyond the imagination of healthy individuals.
Under such circumstances, a technique relating to a composition that promotes salt discharge to the outside of the body has been disclosed (Patent Document 1).
特許文献１には，λ−カラギーナンの金属塩を有効成分とするナトリウムイオン吸収阻害剤に関する発明が開示されており，好ましい金属塩としてカリウムをはじめとするアルカリ金属塩ないしアルカリ土類金属が例示されている。加えて，従来技術として，アルギン酸塩の吸着能が十分満足できるものでなかったことが開示されている。 Patent Document 1 discloses an invention relating to a sodium ion absorption inhibitor containing a metal salt of λ-carrageenan as an active ingredient. Examples of preferable metal salts include alkali metal salts and alkaline earth metals including potassium. ing. In addition, it is disclosed as a prior art that the alginate adsorption ability was not sufficiently satisfactory.
かかる先行技術は，カラギーナンにより消化管内においてナトリウムを吸着し，体外に排出しうる点において有用である。しかるに先行技術は，腎機能障害を持つ患者の場合には，適用が好ましくない点において課題を有するものである。
すなわち，腎機能障害を持つ患者の場合，腎臓からのカリウム排出が十分でないため，高カリウム血症を発症するおそれがある。そのため，腎機能障害を持つ患者は，カリウム制限が必要となるのが通常である。これよりカリウムを好適な金属として適用しうる先行技術は，腎機能障害を持つ患者の場合には，適用が好ましくない点において課題を有するものである。
Such prior art is useful in that sodium can be adsorbed in the digestive tract by carrageenan and excreted from the body. However, the prior art has a problem in that it is not preferable for patients with renal dysfunction.
That is, patients with renal dysfunction may develop hyperkalemia because of insufficient potassium excretion from the kidney. Therefore, patients with renal impairment usually need potassium restriction. Thus, the prior art that can apply potassium as a suitable metal has a problem in that application is not preferable in the case of a patient with renal dysfunction.
先行技術をはじめとして，ナトリウム排出を目的とした組成物として十分確立された技術は未だないのが現状である。これより発明者らは，従来の技術常識にとらわれることなく，エビデンスの明確なナトリウム排出用食品組成物の研究開発に着手したものである。 At present, there is no technology well established as a composition aiming at sodium discharge, including the prior art. Thus, the inventors have started research and development of a food composition for sodium discharge with clear evidence, without being bound by conventional common general knowledge.
上記事情を背景として本発明では，ナトリウム排出を目的とした食品組成物の開発を課題とする。 In view of the above circumstances, an object of the present invention is to develop a food composition for the purpose of sodium discharge.
発明者らは，鋭意研究の結果，従来の技術常識に反し，アルギン酸塩が種々の素材と比較して排塩作用に優れることを明らかにし，アルギン酸塩を有効成分とするナトリウム排出用食品組成物に関する発明を完成させた。
発明者らは，さらに検討を重ね，アルギン酸について，カリウム上昇を抑制したアルギン酸塩を有効成分とするナトリウム排出用食品組成物に関する発明を完成させた。
As a result of diligent research, the inventors have clarified that alginate is superior in salt-removing action as compared with various materials, contrary to conventional common knowledge, and a food composition for sodium discharge containing alginate as an active ingredient. Completed the invention.
The inventors have further studied and completed an invention relating to a food composition for sodium discharge containing alginic acid as an active ingredient for alginic acid, which suppresses an increase in potassium.
本発明は，一態様として，ナトリウム排出用食品組成物として提供される。
［a1］アルギン酸塩（ナトリウム塩を除く）を含有する，ナトリウム排出用食品組成物。
［a2］前記アルギン酸塩がアルギン酸の有機カチオン塩である，［a1］に記載のナトリウム排出用食品組成物。
［a3］有機カチオン塩がアンモニウム塩である，［a2］に記載のナトリウム排出用食品組成物。
［a4］アルギン酸アンモニウムの粘度が，20℃の1%(w/v)濃度において，20から900mPa・sである［a3］に記載のナトリウム排出用食品組成物。
［a5］さらにアルギン酸アンモニウムの粘度が，20℃の1%(w/v)濃度において，100から400mPa・sである［a4］に記載のナトリウム排出用食品組成物。
［a6］さらに，アルギン酸の無機カチオン塩（ナトリウム塩を除く）を含有する，［a2］から［a5］のいずれかに記載のナトリウム排出用食品組成物。
［a7］無機カチオン塩が，カリウム塩，カルシウム塩，マグネシウム塩，鉄塩，および亜鉛塩から選択される１種又は２種以上である，［a6］に記載のナトリウム排出用食品組成物。
［a8］無機カチオン塩が，多価カチオン塩である［a6］に記載のナトリウム排出用食品組成物。
［a9］多価カチオン塩として，少なくともカルシウム塩を含む［a8］に記載のナトリウム排出用食品組成物。
［a10］アルギン酸の有機カチオン塩に対する無機カチオン塩の重量比が0.1〜10である，［a6］から［a9］のいずれかに記載のナトリウム排出用食品組成物。
［a11］ナトリウム含量が，1重量％以下である［a1］から［a10］に記載のナトリウム排出用食品組成物。
［a12］金属含量（ナトリウムを除く）が，0.0001から3.0重量％である［a1］から［a11］に記載のナトリウム排出用食品組成物。
［a13］カプセル剤，散剤，顆粒剤，錠剤，液剤，ゼリー剤，及びグミ剤のいずれかの形態である，［a1］から［a12］のいずれかに記載のナトリウム排出用食品組成物。
［a14］賦形剤，増粘剤・安定化剤，酸化防止剤，pH調整剤，乳化剤，甘味料，酸味料，調味料，着色料，香料，保存料から選択される1種又は2種以上の添加剤を含み，かつ，これらがナトリウムを含まない添加物から選択される［a1］から［a13］のいずれかに記載のナトリウム排出用食品組成物。
［a15］さらに，カリウムを含まない添加物から選択される［a14］に記載のナトリウム排出用食品組成物。
［a16］［a1］から［a15］のいずれかに記載のナトリウム排出用食品組成物であって，腎機能障害の予防を目的に用いられる腎機能障害予防用食品組成物。
In one aspect, the present invention is provided as a food composition for discharging sodium.
[A1] A food composition for discharging sodium, comprising alginate (excluding sodium salt).
[A2] The food composition for sodium discharge according to [a1], wherein the alginate is an organic cation salt of alginic acid.
[A3] The food composition for sodium discharge according to [a2], wherein the organic cation salt is an ammonium salt.
[A4] The sodium discharge food composition according to [a3], wherein the viscosity of ammonium alginate is 20 to 900 mPa · s at a concentration of 1% (w / v) at 20 ° C.
[A5] The sodium drainage food composition according to [a4], wherein the viscosity of ammonium alginate is 100 to 400 mPa · s at a concentration of 1% (w / v) at 20 ° C.
[A6] The food composition for discharging sodium according to any one of [a2] to [a5], further comprising an inorganic cation salt of alginic acid (excluding sodium salt).
[A7] The food composition for sodium discharge according to [a6], wherein the inorganic cation salt is one or more selected from potassium salt, calcium salt, magnesium salt, iron salt, and zinc salt.
[A8] The food composition for discharging sodium according to [a6], wherein the inorganic cation salt is a polyvalent cation salt.
[A9] The food composition for sodium discharge according to [a8], which contains at least a calcium salt as a polyvalent cation salt.
[A10] The food composition for discharging sodium according to any one of [a6] to [a9], wherein the weight ratio of the inorganic cation salt to the organic cation salt of alginic acid is 0.1 to 10.
[A11] The food composition for discharging sodium according to [a1] to [a10], wherein the sodium content is 1% by weight or less.
[A12] The food composition for discharging sodium according to [a1] to [a11], wherein the metal content (excluding sodium) is 0.0001 to 3.0% by weight.
[A13] The food composition for discharging sodium according to any one of [a1] to [a12], which is in the form of a capsule, powder, granule, tablet, liquid, jelly, or gum.
[A14] One or two selected from excipients, thickeners / stabilizers, antioxidants, pH adjusters, emulsifiers, sweeteners, sour agents, seasonings, coloring agents, flavorings, and preservatives The food composition for sodium discharge according to any one of [a1] to [a13], which contains the above additives and is selected from additives not containing sodium.
[A15] The food composition for sodium discharge according to [a14], further selected from additives not containing potassium.
[A16] A food composition for discharging sodium dysfunction according to any one of [a1] to [a15], which is used for the purpose of preventing renal dysfunction.
本発明は，一態様として，食品組成物として提供されるものである。
［b1］アルギン酸塩（ナトリウム塩を除く）を含有する，食品組成物。
［b2］アルギン酸塩がアルギン酸の有機カチオン塩である［b1］に記載の食品組成物。
［b3］アルギン酸の有機カチオン塩の含有量が0.1〜99.9重量％である，［b1］又は［b2］に記載の食品組成物。
［b4］有機カチオン塩がアンモニウム塩である［b2］又は［b3］に記載の食品組成物。
As one aspect, the present invention is provided as a food composition.
[B1] A food composition containing alginate (excluding sodium salt).
[B2] The food composition according to [b1], wherein the alginate is an organic cation salt of alginic acid.
[B3] The food composition according to [b1] or [b2], wherein the content of the organic cation salt of alginic acid is 0.1 to 99.9% by weight.
[B4] The food composition according to [b2] or [b3], wherein the organic cation salt is an ammonium salt.
［b5］さらに，アルギン酸塩アンモニウムを10〜99.9重量％含有する［b4］に記載の食品組成物。
［b6］カプセル剤，散剤，顆粒剤，錠剤のいずれかの形態である，［b1］から［b5］のいずれかに記載の食品組成物。
[B5] The food composition according to [b4], further containing 10 to 99.9% by weight of ammonium alginate.
[B6] The food composition according to any one of [b1] to [b5], which is in the form of a capsule, powder, granule, or tablet.
［b7］さらに，アルギン酸塩アンモニウムを0.1〜10重量％含有する［b4］に記載の食品組成物。
［b8］液剤，ゼリー剤，グミ剤のいずれかの形態である，［b1］から［b4］，ならびに［b7］のいずれかに記載の食品組成物。
[B7] The food composition according to [b4], further containing 0.1 to 10% by weight of ammonium alginate.
[B8] The food composition according to any one of [b1] to [b4] and [b7], which is in the form of any one of a liquid agent, a jelly agent, and a gummi agent.
［b9］さらに，アルギン酸の無機カチオン塩（ナトリウム塩を除く）を含有する，［b2］から［b8］のいずれかに記載の食品組成物。
［b10］無機カチオン塩がカリウム塩，カルシウム塩，マグネシウム塩，鉄塩，および亜鉛塩から選択される１種又は２種以上である，［b9］に記載の食品組成物。
［b11］無機カチオン塩が，多価カチオン塩である［b9］に記載の食品組成物。
［b12］多価カチオン塩として，少なくともカルシウム塩を含む［b11］に記載の食品組成物。
［b13］アルギン酸の有機カチオン塩に対する無機カチオン塩の重量比が0.1〜10である，［b9］から［b12］のいずれかに記載の食品組成物。
［b14］ナトリウム含量が，1重量％以下である［b1］から［b13］に記載のナトリウム排出用食品組成物。
［b15］金属含量（ナトリウムを除く）が，0.0001から3.0重量％である［b1］から［b14］に記載の食品組成物。
［b16］賦形剤，増粘剤・安定化剤，酸化防止剤，pH調整剤，乳化剤，甘味料，酸味料，調味料，着色料，香料，保存料から選択される1種又は2種以上の添加剤を含み，かつ，これらがナトリウムを含まない添加物から選択される［b1］から［b15］のいずれかに記載の食品組成物。
［b17］さらに，カリウムを含まない添加物から選択される［b16］に記載の食品組成物。
［b18］［b1］から［b17］のいずれかに記載の食品組成物であって，ナトリウム排出を目的に用いられるナトリウム排出用食品組成物。
［b19］［b1］から［b17］のいずれかに記載の食品組成物であって，腎機能障害の予防を目的に用いられる腎機能障害予防用食品組成物。
[B9] The food composition according to any one of [b2] to [b8], further comprising an inorganic cation salt of alginic acid (excluding a sodium salt).
[B10] The food composition according to [b9], wherein the inorganic cation salt is one or more selected from potassium salt, calcium salt, magnesium salt, iron salt, and zinc salt.
[B11] The food composition according to [b9], wherein the inorganic cation salt is a polyvalent cation salt.
[B12] The food composition according to [b11], which contains at least a calcium salt as the polyvalent cation salt.
[B13] The food composition according to any one of [b9] to [b12], wherein the weight ratio of the inorganic cation salt to the organic cation salt of alginic acid is 0.1 to 10.
[B14] The food composition for discharging sodium according to [b1] to [b13], wherein the sodium content is 1% by weight or less.
[B15] The food composition according to [b1] to [b14], wherein the metal content (excluding sodium) is 0.0001 to 3.0% by weight.
[B16] One or two selected from excipients, thickeners / stabilizers, antioxidants, pH adjusters, emulsifiers, sweeteners, sour agents, seasonings, coloring agents, flavorings, and preservatives The food composition according to any one of [b1] to [b15], which contains the above additives and is selected from additives not containing sodium.
[B17] The food composition according to [b16], further selected from additives not containing potassium.
[B18] A food composition according to any one of [b1] to [b17], wherein the food composition is used for sodium discharge.
[B19] A food composition according to any one of [b1] to [b17], which is used for the purpose of preventing renal dysfunction.
本発明により，ナトリウム排出を目的とした食品組成物の提供が可能となった。 According to the present invention, it is possible to provide a food composition aimed at sodium discharge.
本発明のナトリウム排出を目的とした食品組成物について説明を行う。 The food composition for the purpose of sodium discharge of the present invention will be described.
本発明のナトリウム排出を目的とした食品組成物は，アルギン酸塩（ナトリウム塩を除く）を含有することを特徴とする。すなわち，アルギン酸が，消化管内においてナトリウムを吸着し，そのまま体外へ排泄される役割を果たすものである。 The food composition for the purpose of sodium discharge of the present invention is characterized by containing alginate (excluding sodium salt). That is, alginic acid plays a role of adsorbing sodium in the digestive tract and excreting it as it is.
アルギン酸は，(C6H8O6)nで表される化合物であり，有効成分として用いる限り特に限定する必要はない。
すなわち，藻類などに含まれる天然由来のものを用いてもよいし，化学的に合成したものを用いてもかまわない。また，アルギン酸は，ナトリウム吸着という本発明の趣旨を損なわない限り，化学構造の一部を置換ないし修飾したものを用いても構わない。
Alginic acid is a compound represented by (C 6 H 8 O 6 ) n and need not be particularly limited as long as it is used as an active ingredient.
That is, a naturally-derived material contained in algae or the like may be used, or a chemically synthesized material may be used. In addition, alginic acid may be used by substituting or modifying a part of the chemical structure as long as the purpose of the present invention of sodium adsorption is not impaired.
アルギン酸塩は，ナトリウム排出の役割を果たす限り特に限定する必要はなく，種々の分子量のものを用いることができる。
アルギン酸塩の粘度平均分子量として，典型的には，100から1,000万のものを用いることができ，より好ましくは1,000から900万，さらに好ましくは1万から900万，特に好ましくは10万から900万，最も好ましくは10万から800万のものを用いることができる。
The alginate is not particularly limited as long as it plays the role of sodium excretion, and those having various molecular weights can be used.
The viscosity average molecular weight of the alginate can be typically from 1 to 10 million, more preferably from 1,000 to 9 million, more preferably from 10,000 to 9 million, particularly preferably from 100,000 to 9 million. , Most preferably 100,000 to 8 million can be used.
アルギン酸塩は，粘度の観点から種々のものを用いることができる。すなわち，アルギン酸塩そのものは同一の分子量を有するものでは通常ないことから，原料として用いる場合に粘度によりこれを特定するものである。
アルギン酸塩の粘度として，典型的には，20℃での1%(w/v)濃度における粘度が10から1000mPa・sのもの，又は20℃での10%(w/v)濃度における粘度が10から3000mPa・sのものを用いればよく，より好ましくは20℃での1%(w/v)濃度における粘度が20から900mPa・s，さらに好ましくは100から900mPa・s，特に好ましくは100から400mPa・s，最も好ましくは300から400mPa・sのものを用いることができる。
Various alginate can be used from the viewpoint of viscosity. That is, since the alginate itself does not usually have the same molecular weight, it is specified by the viscosity when used as a raw material.
The viscosity of alginate typically has a viscosity of 10 to 1000 mPa · s at 1% (w / v) concentration at 20 ° C, or a viscosity at 10% (w / v) concentration at 20 ° C. 10 to 3000 mPa · s may be used, more preferably the viscosity at 20 ° C. at 1% (w / v) concentration is 20 to 900 mPa · s, more preferably 100 to 900 mPa · s, particularly preferably 100 to 100 mPa · s. 400 mPa · s, most preferably 300 to 400 mPa · s can be used.
アルギン酸塩としては，ナトリウム塩でない限り特に限定する必要はなく，種々の塩とすることができる。このような塩として，例えば，有機カチオン塩，カルシウム塩，マグネシウム塩，鉄塩，亜鉛塩などが挙げられる。
なお，本発明におけるアルギン酸塩はナトリウム塩を除外するものであるが，技術的な制限から，微量が混入することまでを排除する趣旨ではない。すなわち，アルギン酸塩は，アルギン酸ナトリウムを原料として，塩の置換反応により化学的に製造される場合があることから，この場合に微量に含まれるナトリウム塩までをも排除する趣旨ではない。
The alginate is not particularly limited as long as it is not a sodium salt, and various salts can be used. Examples of such salts include organic cation salts, calcium salts, magnesium salts, iron salts, and zinc salts.
In addition, although the alginate in this invention excludes a sodium salt, it is not the meaning which excludes until a trace amount mixes from a technical restriction | limiting. In other words, since alginate may be chemically produced from sodium alginate as a raw material by a salt substitution reaction, this does not mean to exclude even a small amount of sodium salt in this case.
アルギン酸塩として，有機カチオン塩を用いることが好ましい。これにより，有効成分からの金属塩の放出を抑制することが可能となり，腎機能に障害を持つ患者などにも安全に適用しうるという効果を有する。
有機カチオン塩としては，アルギン酸塩の形成が可能であり，かつ，安全性を担保しうる限り特に限定する必要はなく，種々の有機カチオンを用いることができる。
As the alginate, an organic cation salt is preferably used. This makes it possible to suppress the release of metal salts from active ingredients, and has the effect that it can be safely applied to patients with impaired renal function.
The organic cation salt is not particularly limited as long as it can form an alginate and can ensure safety, and various organic cations can be used.
アルギン酸有機カチオンの含量は，食品組成物としての形成が可能である限り特に限定する必要はなく，種々の重量比とすることができる。
このような重量比として，例えば，アルギン酸有機カチオンの含量が重量%の下限として，0.1%，1.0%，10.0%，20.0%，30.0%など，重量%の上限として1.0%，10.0%。20.0%，30.0%，40.0%，50.0%，60.0%，70.0%，80.0%，90.0%，99.9%などとすることができる。これらより，例えば，アルギン酸有機カチオンの含量を，0.1から10.0%，0.1から99.9%，10.0から99.9%などとすることができる。
The content of the alginate organic cation is not particularly limited as long as it can be formed as a food composition, and can be various weight ratios.
As such weight ratio, for example, 0.1%, 1.0%, 10.0%, 20.0%, 30.0%, etc., as the lower limit of the content of the organic alginate cation, such as 0.1%, 1.0%, 10.0% as the upper limit of the weight%. 20.0%, 30.0%, 40.0%, 50.0%, 60.0%, 70.0%, 80.0%, 90.0%, 99.9%, etc. From these, for example, the content of the alginate organic cation can be 0.1 to 10.0%, 0.1 to 99.9%, 10.0 to 99.9%, and the like.
有機カチオン塩は，アンモニウム塩（アルギン酸アンモニウム）とすることが好ましい。
これにより，他のアルギン酸塩などと比較して，本発明の食品組成物のナトリウム排出能を，顕著に優れたものとできる効果を有する。加えてアルギン酸アンモニウムは，高すぎない適度な粘性を有することから，取扱性や成形性に優れるという効果を有する。
The organic cation salt is preferably an ammonium salt (ammonium alginate).
Thereby, compared with other alginate etc., it has the effect which can make the sodium discharge | emission ability of the food composition of this invention remarkably excellent. In addition, since ammonium alginate has an appropriate viscosity that is not too high, it has the effect of being excellent in handleability and moldability.
アルギン酸アンモニウムを用いる場合，典型的には，20℃での1%(w/v)濃度における粘度が，20から900mPa・sのものを用いればよい。また，アルギン酸アンモニウムとして，より好ましくは20℃での1%(w/v)濃度における粘度が100から400mPa・s，さらに好ましくは300から400mPa・sのものを用いることできる。
これにより，アルギン酸アンモニウムの取扱性や成形性をさらに向上させることができ，本発明の剤形化をより容易にできる効果を有する。
When ammonium alginate is used, typically, one having a viscosity of 20 to 900 mPa · s at a concentration of 1% (w / v) at 20 ° C. may be used. Further, as ammonium alginate, one having a viscosity at a concentration of 1% (w / v) at 20 ° C. of 100 to 400 mPa · s, more preferably 300 to 400 mPa · s can be used.
Thereby, the handling property and moldability of ammonium alginate can be further improved, and the dosage form of the present invention can be more easily formed.
本発明においてアルギン酸有機カチオンに加えて，さらにアルギン酸無機カチオン（アルギン酸金属塩；ナトリウムを除く）を含有することができる。
これにより，粘度特性の異なるアルギン酸有機カチオンとアルギン酸無機カチオンを組み合わせ食品組成物に対応した粘度特性としつつ，ナトリウム吸着能を保持することが容易となり，本発明の食品組成物の取扱性や成形性を向上させる効果を有する。
アルギン酸有機カチオンとアルギン酸無機カチオンについては，食品組成物の態様により，種々の比率とすることができるが，アルギン酸有機カチオン塩に対するアルギン酸無機カチオンの重量比（アルギン酸無機カチオン重量／アルギン酸有機カチオン重量）を，典型的には，0.05から10，より好ましくは0.1から10，さらに好ましくは0.1から1.0とすることができる。
In the present invention, in addition to the alginic acid organic cation, an alginate inorganic cation (metal alginate; excluding sodium) can be further contained.
This makes it easy to maintain the sodium adsorption ability while combining the viscosity characteristics corresponding to the food composition by combining the alginic acid organic cation and the alginic acid inorganic cation having different viscosity characteristics, so that the food composition of the present invention can be handled and molded. Has the effect of improving.
Alginate organic cation and alginate inorganic cation can be various ratios depending on the form of the food composition, but the weight ratio of alginate inorganic cation to alginic acid organic cation salt (alginate inorganic cation weight / alginate organic cation weight) , Typically from 0.05 to 10, more preferably from 0.1 to 10, and even more preferably from 0.1 to 1.0.
用いるアルギン酸無機カチオンは，ナトリウム塩でない限り特に限定する必要はなく，種々の金属塩を用いることができるが，典型的には，カリウム塩，カルシウム塩，マグネシウム塩，鉄塩，亜鉛塩などから1種もしくは2種以上を選択することができる。
アルギン酸無機カチオンとして，カリウム塩を除くことが好ましい。これにより，本発明の食品組成物摂取後のカリウム放出を防ぐことができ，腎機能に障害を持つ患者などにも安全に適用しうるという効果を有する。
また，アルギン酸無機カチオンとして，多価カチオン塩とすることが好ましい。これにより，アルギン酸塩における金属イオンの含量を少ないままナトリウム排出保持能を維持することが可能となり，本発明の食品組成物摂取後の金属放出を低減することにより，腎機能に障害を持つ患者や高血圧が懸念される健常者などにも安全に適用しうるという効果を有する。
さらに，アルギン酸無機カチオンとして，カルシウム塩を用いることが好ましい。アルギン酸カルシウムは，粘性が特に低いことから，前述の有機カチオン塩と組み合わせることにより，食品組成物としての形成性を向上させ，ナトリウム吸着能を保持しつつ，最適な剤形化を図ることができるという効果を有する。
The alginic acid inorganic cation to be used is not particularly limited as long as it is not a sodium salt, and various metal salts can be used, but typically from potassium salt, calcium salt, magnesium salt, iron salt, zinc salt, etc. Species or two or more can be selected.
As the alginic acid inorganic cation, it is preferable to remove potassium salt. Thereby, the potassium release after ingestion of the food composition of the present invention can be prevented, and it can be safely applied to patients with impaired renal function.
Moreover, it is preferable to use a polyvalent cation salt as the alginic acid inorganic cation. This makes it possible to maintain the ability to retain sodium excretion while maintaining a low content of metal ions in the alginate. By reducing metal release after ingesting the food composition of the present invention, patients with impaired renal function It has the effect that it can be safely applied to healthy people who are concerned about high blood pressure.
Furthermore, it is preferable to use a calcium salt as the alginate inorganic cation. Calcium alginate has a particularly low viscosity. By combining with the above-mentioned organic cation salt, calcium alginate can improve the formability as a food composition, and can achieve an optimal dosage form while maintaining sodium adsorption ability. It has the effect.
本発明の食品組成物において，アルギン酸有機カチオン塩としてアルギン酸アンモニウムを選択し，かつ，これにアルギン酸カルシウムを含んだ組成とすることが好ましい。これにより，本発明の食品組成物のナトリウム吸着能を優れたものとしつつ，食品としての種々の態様に対応しやすい組成とすることができ，本発明の食品組成物の性能ならびにバリエーションを広げることができる効果を有する。
この場合，アルギン酸アンモニウムとアルギン酸カルシウムは，種々の重量比で構成することができるが，アルギン酸塩中のアルギン酸アンモニウムの重量比の下限として，10%，30%，50%，70%，90%など，上限として30%，50%，70%，90%，99%などとすることができる。これより，アルギン酸アンモニウムの重量比として，10から99.9%，30から99.9%，50から99.9%，70から99.9%などとすることができる。
In the food composition of the present invention, it is preferable to select ammonium alginate as the alginate organic cation salt and to contain calcium alginate therein. As a result, the food composition of the present invention has excellent sodium adsorption ability, and can be easily adapted to various aspects of food, and the performance and variations of the food composition of the present invention can be expanded. Has the effect of
In this case, ammonium alginate and calcium alginate can be configured in various weight ratios, but the lower limit of the weight ratio of ammonium alginate in alginate is 10%, 30%, 50%, 70%, 90%, etc. The upper limit may be 30%, 50%, 70%, 90%, 99%, etc. From this, the weight ratio of ammonium alginate can be 10 to 99.9%, 30 to 99.9%, 50 to 99.9%, 70 to 99.9%, and the like.
本発明の食品組成物については，消化管内への摂取が可能である限り特に限定する必要はなく種々の態様を採用することができる。このような態様として，固形食品，半固形食品，及び液体飲料などが挙げられ，例えば，カプセル剤（ハードカプセル及びソフトカプセルを含む），散剤，顆粒剤，錠剤（速崩錠及びチュアブル錠を含む），液剤（果汁飲料，緑茶，紅茶，ウーロン茶，麦茶，コーヒー，炭酸飲料，スポーツ飲料，乳飲料，乳酸菌飲料などの清涼飲料を含む），ゼリー剤，グミ剤などに加え，米飯；そば，うどん，はるさめ，中華麺，即席麺，カップ麺を含む各種の麺類；カレールー，シチュー，各種スープ類；アイスクリーム，アイスシャーベット，かき氷等の冷菓；飴，クッキー，キャンディー，ガム，チョコレート，錠菓，スナック菓子，ビスケット，ジャム，クリーム，その他の焼き菓子等の菓子類；かまぼこ，はんぺん，ハム，ソーセージ等の水産・畜産加工食品；加工乳，発酵乳等の乳製品；サラダ油，てんぷら油，マーガリン，マヨネーズ，ショートニング，ホイップクリーム，ドレッシング等の油脂及び油脂加工食品；ソース，ドレッシング，味噌，醤油，たれ等の調味料；惣菜；ふりかけ；漬物などが挙げられる。 The food composition of the present invention is not particularly limited as long as it can be taken into the digestive tract, and various modes can be adopted. Examples of such embodiments include solid foods, semi-solid foods, and liquid beverages, such as capsules (including hard capsules and soft capsules), powders, granules, tablets (including quick-disintegrating tablets and chewable tablets), In addition to liquid preparations (including fruit juice drinks, green tea, black tea, oolong tea, barley tea, coffee, carbonated drinks, sports drinks, milk drinks, lactic acid bacteria drinks, etc.), jelly preparations, gummi preparations, etc., rice; buckwheat, udon, harusame , Chinese noodles, instant noodles, various types of noodles including cup noodles; Carreru, stew, various soups; ice cream, ice sorbet, shaved ice, etc .; rice cake, cookies, candy, gum, chocolate, tablet confectionery, snack confectionery, biscuits , Jam, cream, other baked goods such as baked goods; fish products such as kamaboko, hanpen, ham, sausage Livestock processed foods; Dairy products such as processed milk and fermented milk; Salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing and other fats and oils processed foods; seasonings such as sauce, dressing, miso, soy sauce, sauce ; Side dish; sprinkle; pickles.
本発明の食品組成物においては，アルギン酸塩に加え，種々の添加物を含むことができる。このような添加物として，例えば，賦形剤，増粘剤・安定化剤，酸化防止剤，pH調整剤，乳化剤，甘味料，酸味料，調味料，着色料，香料，保存料などが挙げられる。 The food composition of the present invention can contain various additives in addition to alginate. Examples of such additives include excipients, thickeners / stabilizers, antioxidants, pH adjusters, emulsifiers, sweeteners, acidulants, seasonings, colorants, fragrances, preservatives, and the like. It is done.
賦形剤としては，例えば，Ｄ−ソルビトール，マンニトール，キシリトール，プロピレングリコールなどの糖アルコール，ブドウ糖，白糖，乳糖，果糖などの糖類，結晶セルロース，リン酸水素カルシウム，コムギデンプン，コメデンプン，トウモロコシデンプン，バレイショデンプン，デキストリン，β−シクロデキストリン，軽質無水ケイ酸，酸化チタン，メタケイ酸アルミン酸マグネシウム，タルク，カオリン，オニオンパウダー，オリーブパウダー，オリーブ油，ゼラチン，カゼイン，ペクチンなどが挙げられる。 Examples of excipients include sugar alcohols such as D-sorbitol, mannitol, xylitol, and propylene glycol, sugars such as glucose, sucrose, lactose, and fructose, crystalline cellulose, calcium hydrogen phosphate, wheat starch, rice starch, and corn starch. Potato starch, dextrin, β-cyclodextrin, light anhydrous silicic acid, titanium oxide, magnesium aluminate metasilicate, talc, kaolin, onion powder, olive powder, olive oil, gelatin, casein, pectin and the like.
増粘剤・安定化剤としては，例えば，ペクチン，デキストラン，グリセリン，多糖類（グァーガム，アラビアガム，キサンタンガム，ジェランガム，スクレロガム，タマリンドシードガム），でんぷん類（ヒドロキシプロピルデンプン，リン酸モノエステル化リン酸架橋デンプン），寒天，ゼラチン，メチルセルロースなどが挙げられる。 Examples of thickeners / stabilizers include pectin, dextran, glycerin, polysaccharides (guar gum, gum arabic, xanthan gum, gellan gum, sclero gum, tamarind seed gum), starches (hydroxypropyl starch, phosphate monoesterified phosphorus) Acid-crosslinked starch), agar, gelatin, methylcellulose and the like.
酸化防止剤としては，例えば，L-アスコルビン酸類（L-アスコルビン酸，L-アスコルビン酸カルシウム，L-アスコルビン酸ステアリン酸エステル，L-アスコルビン酸パルミチン酸エステル），エリソルビン酸，ブチルヒドロキシアニソール，γ-オリザノール，カテキン，カンゾウ油性抽出物，クエルセチン，クエン酸，モノクエン酸グリセリル，トコトリエノール，トコフェロール類（d-α-トコフェロール，d-γ-トコフェロール，d-δ-トコフェロール），レシチン，フェルラ酸，メラロイカ精油，ヒマワリ種子抽出物，ブドウ種子抽出物，プロポリス抽出物，ヘゴ・イチョウ抽出物，ヤマモモ抽出物，ローズマリー抽出物などが挙げられる。 Antioxidants include, for example, L-ascorbic acids (L-ascorbic acid, calcium L-ascorbate, L-ascorbic acid stearate, L-ascorbic acid palmitate), erythorbic acid, butylhydroxyanisole, γ- Oryzanol, catechin, licorice oily extract, quercetin, citric acid, glyceryl monocitrate, tocotrienol, tocopherols (d-α-tocopherol, d-γ-tocopherol, d-δ-tocopherol), lecithin, ferulic acid, melaleuica essential oil, Examples include sunflower seed extract, grape seed extract, propolis extract, hego-ginkgo extract, bayberry extract, rosemary extract, and the like.
pH調整剤としては，例えば，クエン酸，グルコン酸，コハク酸，リンゴ酸，リン酸，マレイン酸，酒石酸，乳酸，乳酸カルシウム，酢酸アンモニウム，メグルミン，グルコノ−δ−ラクトンなどを用いることができる。 As the pH adjuster, for example, citric acid, gluconic acid, succinic acid, malic acid, phosphoric acid, maleic acid, tartaric acid, lactic acid, calcium lactate, ammonium acetate, meglumine, glucono-δ-lactone and the like can be used.
乳化剤としては，例えば，ステアリルトリエタノールアミン，ラウリル硫酸ナトリウム，ラウリルアミノプロピオン酸，レシチン，塩化ベンザルコニウム，塩化ベンゼトニウム，モノステアリン酸グリセリンなどの界面活性剤；例えばポリビニルアルコール，ポリビニルピロリドン，カルボキシメチルセルロースナトリウム，メチルセルロース，ヒドロキシメチルセルロース，ヒドロキシエチルセルロース，ヒドロキシプロピルセルロースなどの親水性高分子；例えばシェラックロウ，ミツロウ，カルナバロウ，鯨ロウ，ラノリン，液状ラノリン，還元ラノリン，硬質ラノリン，環状ラノリン，ラノリンワックス，キャンデリラロウ，モクロウ，モンタンロウ，セラックロウ，ライスワックスなどワックス類，ショ糖脂肪酸エステル，ソルビタン脂肪酸エステル，プロピレングリコール脂肪酸エステル，グリセリン脂肪酸エステル，ステアロイル乳酸カルシウム，クエン酸カルシウム，リン酸カルシウム塩類，エンジュサポニン，ダイズサポニン，チャ種子サポニン，ビートサポニン，スフィンゴ脂質，トマト糖脂質，植物性ステロール，植物レシチン，酵素分解レシチン，卵黄レシチン,ユッカフォーム抽出物，オオムギ殻皮抽出物，キラヤ抽出物などが挙げられる。 Examples of the emulsifier include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate; for example, polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose , Methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and other hydrophilic polymers; eg shellac wax, beeswax, carnauba wax, whale wax, lanolin, liquid lanolin, reduced lanolin, hard lanolin, cyclic lanolin, lanolin wax, candelilla wax , Wax, such as molasses, montan wax, shellac wax, rice wax, sucrose fatty acid ester, sorbi Fatty acid ester, propylene glycol fatty acid ester, glycerin fatty acid ester, stearoyl calcium lactate, calcium citrate, calcium phosphate salts, enjusaponin, soybean saponin, tea seed saponin, beet saponin, sphingolipid, tomato glycolipid, plant sterol, plant lecithin , Enzyme-degraded lecithin, egg yolk lecithin, yucca foam extract, barley husk extract, kiraya extract, and the like.
甘味料として，例えば，サッカリン類，糖質類，コーンシロップ，アスパルテーム，エリスリトール，D-ソルビトール，D-キシロース，D-リボース，L-アラビノース，L-ソルボース，L-フコース，L-ラムノース，ソーマチン，アセスルファムK，クルクリン，タウマチン，ステビア抽出物，カンゾウ抽出物，テンリョウチャ抽出物，ナイゼリアベリー抽出物などを用いることができる。 Examples of sweeteners include saccharin, carbohydrates, corn syrup, aspartame, erythritol, D-sorbitol, D-xylose, D-ribose, L-arabinose, L-sorbose, L-fucose, L-rhamnose, thaumatin, Acesulfame K, curculin, thaumatin, stevia extract, licorice extract, tenryocha extract, Neiseria berry extract and the like can be used.
酸味料として，例えば，アジピン酸，クエン酸，グルタコノデルタラクトン，グルコン酸，コハク酸，酒石酸，炭酸ガス，乳酸，酢酸，氷酢酸，フマル酸，リンゴ酸，リン酸，イタコン酸，α-ケトグルタル酸，フィチン酸などを用いることができる。 Examples of acidulants include adipic acid, citric acid, glutacono delta lactone, gluconic acid, succinic acid, tartaric acid, carbon dioxide, lactic acid, acetic acid, glacial acetic acid, fumaric acid, malic acid, phosphoric acid, itaconic acid, α-ketoglutar Acid, phytic acid, etc. can be used.
調味料として，例えば，アミノ酸類，核酸類，有機酸類，無機塩類を用いることができる。 As a seasoning, for example, amino acids, nucleic acids, organic acids, and inorganic salts can be used.
着色料としては，例えば，β−アポ−８’−カロテナール，β-ガラクトシダーゼ，クロロフィリン，クロロフィル，鉄クロロフィリンナトリウム，イモカロテン，タール色素，アカネ色素，アナトー色素，アルカネット色素，ウコン色素，オレンジ色素，カカオ色素，カラメル類，クサギ色素，カロブ色素，クチナシ色素類，クーロー色素，オレンジ果汁，エルダーベリー果汁，クランベリー果汁，ストロベリー果汁，チェリー果汁，パイナップル果汁，ブドウ果汁，プラム果汁，ブルーベリー果汁，ラズベリー果汁，レモン果汁などを用いることができる。 Examples of the coloring agent include β-apo-8′-carotenal, β-galactosidase, chlorophyllin, chlorophyll, iron chlorophyllin sodium, imocarotene, tar dye, akane dye, anato dye, alkane dye, turmeric dye, orange dye, cacao. Pigment, caramel, wedge, carob pigment, gardenia pigment, coulomb pigment, orange juice, elderberry juice, cranberry juice, strawberry juice, cherry juice, pineapple juice, grape juice, plum juice, blueberry juice, raspberry juice, lemon Fruit juice or the like can be used.
着香料としては，例えば，イソチオシアネート類，インドール類，エステル類，エーテル類，ケトン類，脂肪酸類，脂肪族高級アルコール類，脂肪族高級アルデヒド類，高級単価水素類，チオアルコール類，チオエーテル類，テルペン系炭化水素類，フェノールエーテル類，フェノール類，フルフラール類，芳香族アルコール類，芳香族アルデヒド類，ラクトン類などを用いることができる。 Examples of flavoring agents include isothiocyanates, indoles, esters, ethers, ketones, fatty acids, higher aliphatic alcohols, higher aliphatic aldehydes, higher unit price hydrogens, thioalcohols, thioethers, Terpene hydrocarbons, phenol ethers, phenols, furfurals, aromatic alcohols, aromatic aldehydes, lactones, and the like can be used.
保存料としては，例えば，安息香酸類，イマザリル，オルトフェニルフェノール，ジフェニル，ソルビン酸，チアベンダゾール，プロピオン酸，ウド抽出物，エゴノキ抽出物，カワラヨモギ抽出物，ツヤプリシン抽出物，ペクチン分解物，ホオノキ抽出物，レンギョウ抽出物などが挙げられる。 Preservatives include, for example, benzoic acids, imazalyl, orthophenylphenol, diphenyl, sorbic acid, thiabendazole, propionic acid, udo extract, egonoki extract, kawara mugwort extract, tsuyaprisin extract, pectin degradation product, honoki extract, Forsythia extract and the like.
本発明において，これら賦形剤，増粘剤・安定化剤，酸化防止剤，pH調整剤，乳化剤，甘味料，酸味料，調味料，着色料，香料，保存料などの添加物は，アルギン酸塩の性能を損なわないよう，ナトリウムを用いない添加物を選択することが好ましい。さらには，ナトリウムと合わせてカリウムをも用いない添加物を選択することが好ましい。
本発明において，「ナトリウムを含まない添加物」ないし「カリウムを含まない添加物」とは，これらの金属イオンを構成分子ないし構成成分として含まない添加物として定義される。また，「ナトリウムを含まない添加物を選択」ないし「カリウムを含まない添加物を選択」とは，本発明において，これらの金属イオンを構成分子ないし構成成分として含む添加物を除外するものとして定義されるが，完全に排除する趣旨ではない。
すなわち，例えば，添加物の目的以外の十分な効能・効果を奏することなく，権利の迂回を目的としてこれらの金属イオンを構成分子として含む添加物を選択し，食品組成物としてわずかながら含むことは，本発明の趣旨に沿った添加物の使用として権利の及ぶものである。このような迂回的な使用の目安として，例えば，食品組成物中のナトリウムないしカリウムの金属イオンの重量比率が典型的には1%以下，もしくは0.5%以下，さらには0.3%以下であり，アルギン酸塩に対するナトリウムないしカリウムの金属イオン重量比率が典型的には10%以下，もしくは5%以下，または3%以下，1%以下などである。
In the present invention, these excipients, thickeners / stabilizers, antioxidants, pH adjusters, emulsifiers, sweeteners, acidulants, seasonings, colorants, fragrances, preservatives and the like are alginic acid. It is preferable to select an additive that does not use sodium so as not to impair the performance of the salt. Furthermore, it is preferable to select an additive that does not use potassium in combination with sodium.
In the present invention, “additives not containing sodium” or “additives not containing potassium” are defined as additives that do not contain these metal ions as constituent molecules or constituents. In addition, “select an additive that does not contain sodium” or “select an additive that does not contain potassium” is defined in the present invention as excluding additives containing these metal ions as constituent molecules or constituents. It is not intended to be completely excluded.
That is, for example, an additive containing these metal ions as a constituent molecule is selected for the purpose of circumventing the rights without exhibiting sufficient efficacy and effects other than the purpose of the additive, and a slight amount of food composition is included. The use of additives in accordance with the spirit of the present invention is covered by the rights. As a guideline for such detour use, for example, the weight ratio of sodium or potassium metal ions in the food composition is typically 1% or less, 0.5% or less, and 0.3% or less. The weight ratio of metal ions of sodium or potassium to salt is typically 10% or less, or 5% or less, or 3% or less, 1% or less.
本発明の食品組成物において，金属成分含量（ナトリウムを除く）を少なく抑えることが好ましい。これにより，有効成分によるナトリウム排出と食品組成物による金属塩摂取の最小化を図ることが可能となり，腎機能に障害を持つ患者や高血圧が懸念される健常者などにも安全に適用しうるとともに，本発明の食品組成物の効果を最大化することができる効果を有する。
金属成分含量（ナトリウムを除く）については，典型的には，その重量比の下限として0%，0.0001%，0.001%，0.01%などであり，上限として0.1%，1.0%，3.0%，5.0%などから選択することができ，これにより，食品組成物全体における金属塩の重量比率として，例えば，0.0001%から5.0%，0.001%から5.0%，0.01%から5.0%などとすることができる。
In the food composition of the present invention, it is preferable to keep the metal component content (excluding sodium) low. This makes it possible to minimize sodium excretion by the active ingredient and metal salt intake by the food composition, and can be safely applied to patients with impaired renal function or healthy subjects with high blood pressure. , It has the effect of maximizing the effect of the food composition of the present invention.
For metal component contents (excluding sodium), the lower limit of the weight ratio is typically 0%, 0.0001%, 0.001%, 0.01%, etc., and the upper limit is 0.1%, 1.0%, 3.0%, 5.0%. Thus, the weight ratio of the metal salt in the whole food composition can be set to, for example, 0.0001% to 5.0%, 0.001% to 5.0%, 0.01% to 5.0%, and the like.
本発明の食品組成物について，摂取する時間は特に限定されるものではないが，ナトリウムの排出効果をより顕著に奏するという観点から，食前に摂取することが好ましい。 The time for ingestion of the food composition of the present invention is not particularly limited, but it is preferably ingested before meals from the viewpoint of more remarkable sodium draining effect.
また，本発明の食品組成物については，１回あたりの摂取量は得に限定されるものではないが，ナトリウムの排出効果をより顕著に奏するという観点から，アルギン酸塩（ナトリウム塩を除く）として，１回あたり10〜5000mgが好ましく，50〜3000mgがより好ましく，100〜1000mgがさらに好ましい。 Moreover, about the food composition of this invention, although the intake per time is not limited to a profit, from the viewpoint of exhibiting the discharge | release effect of sodium more notably, as an alginate (except sodium salt) , 10-5000 mg per dose is preferred, 50-3000 mg is more preferred, and 100-1000 mg is even more preferred.
本発明の食品組成物は，その用途としてナトリウム排出用として用いられるが，さらには，腎機能障害の予防を目的に腎機能障害予防用食品組成物としても用いることができる。
本発明における腎機能障害予防用とは，狭義には，腎機能に障害を既に有している者を対象として，透析患者，腎不全患者，糖尿病患者などに対して用いられるものとして定義され，広義には，腎機能に障害を有していないものの，これが懸念される者として，高血圧，肥満体質などの健常人に対して用いられるものとして定義される。
The food composition of the present invention is used for sodium excretion as its use, and can also be used as a food composition for preventing renal dysfunction for the purpose of preventing renal dysfunction.
For prevention of renal dysfunction in the present invention, in a narrow sense, for those who already have impaired renal function, it is defined as used for dialysis patients, renal failure patients, diabetic patients, etc. In a broad sense, it is defined as being used for healthy individuals with high blood pressure, obesity, etc. as those who are not concerned about renal function but are concerned about this.
本発明の食品組成物は，ナトリウム排出用ないし腎機能障害予防用など，これらの用途を備えた機能性表示食品，特定保健食品等の保健機能食品，特別用途食品などとして用いることができる。 The food composition of the present invention can be used as a functional display food having these uses such as sodium discharge or renal function disorder prevention, health functional foods such as specified health foods, special use foods, and the like.
ここでは，実施例を用いて，本発明のナトリウム排出用食品組成物についてさらに詳述するが，本発明の内容を実施例に限定して解釈すべきでないことはいうまでもない。 Here, although the food composition for sodium discharge | emission of this invention is further explained in full detail using an Example, it cannot be overemphasized that the content of this invention should not be limited and limited to an Example.
＜＜実験１，各サンプルを用いた塩化ナトリウム吸着実験＞＞
各サンプルについて，スクリーニング的に，塩化ナトリウムに対する吸着能を調べることを目的に検討を行った。
<< Experiment 1, sodium chloride adsorption experiment using each sample >>
Each sample was screened for the purpose of examining the adsorption capacity for sodium chloride.
＜実験方法＞
１．遠沈管に１％塩化ナトリウム溶液を分注した。この遠沈管１本に対し，各サンプルを加えて混和し，10分間以上，室温にて静置した。
２．コンパクト塩分計（HORIBA Scientific，型式B-721）にて，遠沈管内溶液のナトリウム濃度の測定を行った。
３．また，コントロールとして，サンプルを加えず同様の操作で測定を行った。このコントロールにおけるナトリウム濃度測定値を100%として，各サンプルにおける吸着能の評価を行った。すなわち，値が小さければ小さいほど，水溶液中に遊離するナトリウムの濃度が低く，サンプルへのナトリウム吸着能が大きいことを示している。
４．なお，コントロールを含むすべてのサンプルについて，ｎ＝３で検討を行った。
<Experiment method>
1. A 1% sodium chloride solution was dispensed into the centrifuge tube. Each sample was added to this centrifuge tube, mixed, and allowed to stand at room temperature for 10 minutes or longer.
2. The sodium concentration of the solution in the centrifuge tube was measured with a compact salinity meter (HORIBA Scientific, model B-721).
3. As a control, the measurement was performed in the same manner without adding a sample. The sodium concentration measured in this control was taken as 100%, and the adsorption capacity of each sample was evaluated. That is, the smaller the value, the lower the concentration of sodium liberated in the aqueous solution, indicating that the sodium adsorption capacity to the sample is greater.
4). All samples including the control were examined with n = 3.
１．結果を表１に示す。
(1) 検討を行ったサンプルのうち，複数のサンプルで100%に満たない値を示した。
(2) 特に，実験例１（PAL），実験例４（GEG），実験例１６（CAL），実験例１７（AAL）は，90%に満たない値であり，優れた吸着能を示した。
(3) この中でも，実験例１７のアルギン酸アンモニウムは，特に優れた吸着能を示した。なお，このアルギン酸アンモニウムについては，推定分子量が10万から900万，20℃における1%(w/v)濃度溶液の粘度が300から400mPa・sのものを用いた。
２．これらの結果より，以降の検討では，実験例１，実験例４，実験例１６，実験例１７について，詳細に検討を行うこととした。
1. The results are shown in Table 1.
(1) Among the samples examined, multiple samples showed values less than 100%.
(2) In particular, Experimental Example 1 (PAL), Experimental Example 4 (GEG), Experimental Example 16 (CAL), and Experimental Example 17 (AAL) were less than 90% and showed excellent adsorption ability. .
(3) Among these, the ammonium alginate of Experimental Example 17 showed particularly excellent adsorption ability. The ammonium alginate was used with an estimated molecular weight of 100,000 to 9 million and a 1% (w / v) concentration viscosity at 20 ° C of 300 to 400 mPa · s.
2. From these results, in the following examination, it was decided to examine in detail about Experimental Example 1, Experimental Example 4, Experimental Example 16, and Experimental Example 17.
＜＜実験２，サンプル濃度の検討＞＞
実験１の検討より，吸着能に優れると思われるサンプルが見い出されたことから，これらについて，濃度をふってさらに検討を行った。
<< Experiment 2, examination of sample concentration >>
From the examination in Experiment 1, samples that were considered to be excellent in adsorption capacity were found, and these were further examined by varying the concentration.
＜実験方法＞
１．実験１と同様の手法により行った。
２．なお，遠沈管に添加するサンプルについては，1/2倍，1倍，2倍，4倍量とし，この際，溶液粘度が高すぎるものについては除外した。
<Experiment method>
1. The same method as in Experiment 1 was performed.
2. Samples added to the centrifuge tube were halved, 1x, 2x, and 4x, and samples with too high solution viscosity were excluded.
＜実験結果＞
１．結果を，表２に示す。
２．すべてのサンプルで，サンプル濃度依存的に，遊離塩化ナトリウム濃度は減少していた。
３．これより，すべてのサンプルにおいて，濃度依存的にナトリウムを吸着しているものと考えられた。
４．この中でも，アルギン酸アンモニウムは，特に優れた吸着能を示した。加えて，PALやGEGにおいては高濃度になると溶液粘度が高くなりすぎる一方，アルギン酸アンモニウムやアルギン酸カルシウムは溶液粘度の観点からそのような現象はおこらず，取扱性に優れることが分かった。
<Experimental result>
1. The results are shown in Table 2.
2. In all samples, free sodium chloride concentration decreased depending on the sample concentration.
3. From this, it was considered that sodium was adsorbed in a concentration-dependent manner in all samples.
4). Among these, ammonium alginate showed particularly excellent adsorption ability. In addition, it was found that the solution viscosity becomes too high at high concentrations in PAL and GEG, while ammonium alginate and calcium alginate do not exhibit such a phenomenon from the viewpoint of solution viscosity and are excellent in handleability.
＜＜実験３．pHによる測定値の比較＞＞
各サンプルについて，消化管におけるナトリウム吸着を想定し，pHをふって検討を行った。
<< Experiment 3. Comparison of measured values by pH >>
For each sample, we considered sodium adsorption in the gastrointestinal tract and examined the pH.
＜実験方法＞
１．実験１と同様の手法で行い，サンプルについては，1倍量にて検討を行った。
２．なお，1%塩化ナトリウム溶液については，pH未調整のもの（pH6.8）に加え，胃内を想定するとともに測定機器の測定限界であるpH3.0のものを用いて検討を行った。pHの調整については，1N塩酸を用いた。
３．また，測定については，ナトリウム濃度に加え，カリウム濃度を，コンパクトカリウム計（HORIBA Scientific, 型式B731）にて測定を行った。
<Experiment method>
1. The procedure was the same as in Experiment 1, and the sample was examined with a single amount.
2. For 1% sodium chloride solution, in addition to the unadjusted pH (pH 6.8), we considered the gastric and pH 3.0, which is the measurement limit of the measuring instrument. For adjustment of pH, 1N hydrochloric acid was used.
3. In addition to the sodium concentration, the potassium concentration was measured with a compact potassium meter (HORIBA Scientific, model B731).
＜実験結果＞
１．ナトリウム濃度の測定結果を表３の左に示す。
(1) いずれのサンプルにおいても，pH3.0における検討において，遊離ナトリウム濃度が高い値を示した。
(2) この中で，AALについてはほとんど変わらない値を示した。
２．カリウム濃度の測定結果を表３の右に示す。
(1) PAL，GEGについてカリウム濃度の大きな増加がみられた。これらについては，サンプルそのものがカリウム塩として構成されていることから，ナトリウムと置換することにより，カリウムが遊離したものと考えられた。
(2) AALについて，カリウム濃度の若干の増加がみられた。これについては，サンプル中に不純物としてカリウムが含まれていることが要因と思われた。
(3) CALでは，カリウム濃度の増加は見られなかった。
３．これらの結果から，アルギン酸アンモニウムは，酸性条件においても優れたナトリウム吸着能を保持していることが分かった。加えて，アルギン酸アンモニウムならびにアルギン酸カルシウムでは，他のサンプルと比較して，遊離カリウム濃度が低いことが分かった。
<Experimental result>
1. The measurement result of the sodium concentration is shown on the left side of Table 3.
(1) In all samples, free sodium concentration was high in the study at pH 3.0.
(2) Among them, AAL showed almost the same value.
2. The measurement result of potassium concentration is shown on the right side of Table 3.
(1) A significant increase in potassium concentration was observed for PAL and GEG. About these, since the sample itself was comprised as potassium salt, it was thought that potassium was liberated by substituting with sodium.
(2) For AAL, there was a slight increase in potassium concentration. This was thought to be caused by the inclusion of potassium as an impurity in the sample.
(3) With CAL, there was no increase in potassium concentration.
3. From these results, it was found that ammonium alginate retained excellent sodium adsorption ability even under acidic conditions. In addition, ammonium alginate and calcium alginate were found to have lower free potassium levels than other samples.
＜＜実験４．塩分吸着能の検討＞＞
各サンプルについて，インビボにおいての効果を確認すべく，検討を行った。
<< Experiment 4. Examination of salt adsorption ability >>
Each sample was examined to confirm the in vivo effect.
＜実験方法＞
１．マウスに，各サンプル，塩化ナトリウムの順で，経口投与を行った。
２．上記サンプル等の投与前，投与後１時間，２時間において，それぞれマウス眼窩静脈から採血を行った。
３．採血した血液について遠心分離を行い，血漿成分のナトリウム濃度ならびにカリウム濃度の測定を行った。
<Experiment method>
1. Mice were orally administered in the order of each sample and sodium chloride.
2. Blood was collected from the mouse orbital vein before and 1 hour and 2 hours after the administration of the above samples and the like.
3. The collected blood was centrifuged and the plasma sodium and potassium concentrations were measured.
＜実験結果＞
１．サンプル間で比較したナトリウム濃度ならびに抑制率の結果を表４に示す。なお，抑制率については，各時間点のコントロールにおけるナトリウム濃度増加分を100%としてこれをどれだけ抑制したの観点から，下記式（数１）に従い，算出した。
<Experimental result>
1. Table 4 shows the results of the sodium concentration and the inhibition rate compared between the samples. In addition, about the suppression rate, it calculated according to the following formula (Equation 1) from the viewpoint of how much this was controlled by setting the sodium concentration increase in the control at each time point as 100%.
(1) コントロールにおいて，投与後１時間において，血漿中ナトリウム濃度が0.90%まであがり，投与後２時間においては，0.78%とやや下がった値であったが，投与前よりも高い値に落ち着いていた。
(2) PALでは，投与後１時間において血漿中ナトリウム濃度が0.87%，投与後２時間で0.74%と，コントロールと比較して低い値であった。また，抑制率では，投与後１時間において11.1%，投与後2時間において26.67%であった。
(3) CALでは，投与後１時間において血漿中ナトリウム濃度が0.79%，投与後２時間で0.67%と，コントロールと比較して大きく低下していた。また，抑制率では，投与後１時間において40.74%，投与後2時間において73.33%と大きな値を示した。
(4) AALでは，投与後１時間において血漿中ナトリウム濃度が0.77%，投与後２時間で0.68%と，コントロールと比較して大きく低下していた。また，抑制率では，投与後１時間において48.15%，投与後2時間において66.67%と大きな値を示した。
２．これらの結果から，いずれのサンプルにおいてもインビボにおける血漿中ナトリウム濃度の上昇抑制効果が確認された。その中においても，CALならびにAALでは，極めて優れたナトリウムの排出効果が確認された。また，AALは，CALの半分の投与量でCALと同等の効果を示したことから，血漿中ナトリウム濃度の上昇抑制効果に最も優れることが確認された。
(1) In the control, the plasma sodium concentration rose to 0.90% at 1 hour after administration, and decreased slightly to 0.78% at 2 hours after administration, but remained at a higher value than before administration. It was.
(2) With PAL, the sodium concentration in plasma was 0.87% 1 hour after administration, and 0.74% 2 hours after administration, which was lower than the control. The suppression rate was 11.1% 1 hour after administration and 26.67% 2 hours after administration.
(3) In CAL, the sodium concentration in plasma was 0.79% 1 hour after administration, and 0.67% 2 hours after administration, which was a significant decrease compared to controls. The inhibition rate was 40.74% 1 hour after administration and 73.33% 2 hours after administration.
(4) In AAL, the sodium concentration in plasma was 0.77% at 1 hour after administration, and 0.68% at 2 hours after administration, which was significantly lower than the control. The inhibition rate was 48.15% 1 hour after administration and 66.67% 2 hours after administration.
2. From these results, in any sample, the effect of suppressing the increase of the sodium concentration in plasma in vivo was confirmed. Among them, CAL and AAL were confirmed to have an excellent sodium discharge effect. In addition, AAL showed the same effect as CAL at half the dose of CAL, confirming that it was most effective in suppressing the increase in plasma sodium concentration.
３．カリウム濃度測定結果を表５に示す。
(1) コントロールにおいて，投与後１時間において，血漿中ナトリウム濃度が213ppmまであがり，投与後２時間においては，195ppmとやや下がった値であったが，投与前よりも高い値に落ち着いていた。
(2) PALでは，投与後１時間で200ppm，投与後２時間で270ppmと経時的に増加していった。これは，PALのカリウムがナトリウムと置換することにより放出され，消化管より吸収された影響と考えられる。
(3) CALでは，投与後１時間で183ppm，投与後２時間で173ppmと，コントロールと比較して低下していた。
(4) AALでは，投与後１時間で170ppm，投与後２時間で198ppmと，コントロールと比較して低下していた。
４．これらの結果から，PALでは血漿中カリウム濃度上昇の影響が大きくみられる一方，CALならびにAALでは，血漿中におけるカリウム濃度増加の影響はほとんどないといえる。
3. Table 5 shows the measurement results of potassium concentration.
(1) In the control, the plasma sodium concentration increased to 213 ppm at 1 hour after administration, and decreased slightly to 195 ppm at 2 hours after administration, but remained at a higher value than before administration.
(2) PAL increased over time to 200 ppm 1 hour after administration and 270 ppm 2 hours after administration. This is thought to be the effect that PAL potassium was released by replacing sodium and absorbed from the digestive tract.
(3) With CAL, it was 183 ppm 1 hour after administration and 173 ppm 2 hours after administration, which was lower than the control.
(4) AAL decreased to 170 ppm 1 hour after administration and 198 ppm 2 hours after administration, compared to the control.
4). From these results, it can be said that PAL has a large effect on plasma potassium concentration, while CAL and AAL have almost no effect on plasma potassium concentration.
５．アルギン酸アンモニウムにおいて，投与濃度を振って検討した結果を表５に示す。
(1) いずれの投与量においても，投与後15分から，コントロールと比較して低い血漿中ナトリウム濃度を示し，その傾向は，投与後1時間，投与後2時間においても確認された。
(2) また，投与量が増えるほど血漿中ナトリウム濃度が低い傾向にあり，濃度依存的に血漿中ナトリウム濃度を抑制することが分かった。
5. Table 5 shows the results of examination with different dosage concentrations for ammonium alginate.
(1) At any dose, the plasma sodium concentration was lower than that of the control at 15 minutes after administration, and this tendency was confirmed at 1 hour and 2 hours after administration.
(2) In addition, the plasma sodium concentration tended to decrease as the dose increased, and it was found that the plasma sodium concentration was suppressed in a concentration-dependent manner.
６．アルギン酸カルシウムにおいて，投与濃度を振って検討した結果を表６に示す。本検討においてはコントロールの検討を行っていないが，投与量が増えるほど血漿中ナトリウム濃度が低い傾向にあり，濃度依存的に血漿中ナトリウム濃度を抑制すると考えられた。 6). Table 6 shows the results of examining the administration concentration of calcium alginate. Although control was not examined in this study, the sodium concentration in plasma tended to decrease as the dose increased, and it was considered that the sodium concentration in plasma was suppressed in a concentration-dependent manner.
＜＜実験５．試作例を用いたインビトロにおける検討＞＞
これまでの結果から，アルギン酸アンモニウムならびにアルギン酸カルシウムを有効成分とした試作例を作製し，その効果を調べた。
<< Experiment 5. In vitro study using prototype examples >>
Based on the results so far, we made a prototype with ammonium alginate and calcium alginate as active ingredients and investigated the effects.
＜実験方法＞
検討を行った各試作例について，実験３の方法に準じて，検討を行った。
<Experiment method>
Each prototype that was studied was examined according to the method of Experiment 3.
１．アルギン酸アンモニウム，アルギン酸カルシウム，オニオンパウダー（賦形剤）を有効成分とした試作例を用いて検討を行った結果を表８に示す。なお，各試作例について，有効成分濃度を１倍量として検討を行った。
２．全ての試作例において，遊離塩化ナトリウム濃度ならびに遊離カリウム濃度は低下していた。
３．これらのうち，溶液粘度を考慮して，試作例２，試作例５，試作例９の成分組成をより有用性の高い組成と判断し，以降の検討を行った。
1. Table 8 shows the results of studies conducted using prototype examples in which ammonium alginate, calcium alginate, and onion powder (excipient) were used as active ingredients. In addition, about each trial example, the active ingredient density | concentration was considered as 1 time amount.
2. In all prototypes, free sodium chloride concentration and free potassium concentration decreased.
3. Of these, considering the solution viscosity, the component compositions of Prototype Example 2, Prototype Example 5 and Prototype Example 9 were judged to be more useful compositions, and the following examination was performed.
４．試作例２，試作例５，試作例９の成分組成に準じた試作例について，成分濃度をふって検討を行った結果を表７に示す。
５．全ての試作例について，遊離ナトリウム濃度は低下していた。一方，遊離カリウム濃度については，試作例１６ならびに試作例１９を除き，低下していた。
６．これらのうち，溶液粘度を考慮すると，試作例１４，試作例１５，試作例１７，試作例２０，試作例２１が，より優れた効果を発揮するものと考えられた。
4). Table 7 shows the results of investigations based on the component concentrations of the prototypes according to the component compositions of prototype example 2, prototype example 5, and prototype example 9.
5. In all prototypes, free sodium concentrations were reduced. On the other hand, the free potassium concentration was decreased except for Prototype 16 and Prototype 19.
6). Among these, in consideration of the solution viscosity, it was considered that Prototype Example 14, Prototype Example 15, Prototype Example 17, Prototype Example 20, and Prototype Example 21 exhibited more excellent effects.
７．賦形剤として，オリーブパウダーを用いて検討を行った結果を表１０に示す。なお，各試作例について，有効成分濃度を１倍量として検討を行った。
８．全ての試作例で，遊離ナトリウム濃度は低下していた。
９．一方，遊離カリウム濃度は，試作例２５を除き，増加していた。
(1) 試作例２３から試作例２５については，試作例１５，試作例１８，試作例２１と同様の検討であり，異なるのは，賦形剤成分のみである。
(2) 試作例２３等については，いずれも試作例１５等と比較して，遊離カリウム濃度が高かったことから，オリーブパウダー由来のカリウムであるものと思われた。
7). Table 10 shows the results of investigation using olive powder as an excipient. In addition, about each trial example, the active ingredient density | concentration was considered as 1 time amount.
8). In all prototypes, free sodium concentrations were reduced.
9. On the other hand, the free potassium concentration was increased except for 25 prototypes.
(1) For Trial Example 23 to Trial Example 25, the examination is similar to Trial Example 15, Trial Example 18, and Trial Example 21, and only the excipient component is different.
(2) About trial example 23 etc., since free potassium concentration was high compared with trial manufacture example 15 etc., it was thought that it was potassium derived from olive powder.
＜＜実験６．試作例を用いたインビボにおける検討＞＞
これまでの結果から，試作例２，試作例５，試作例９が排塩剤としてより有用と判断し，これらの組成成分を持った試作例を用いて，インビボにおける検討を行った。
<< Experiment 6. In vivo study using prototype example >>
From the results so far, it was judged that Prototype Example 2, Prototype Example 5 and Prototype Example 9 were more useful as salt-removing agents, and in vivo studies were conducted using trial examples having these composition components.
＜実験方法＞
実験４に準じて，検討を行った。
<Experiment method>
A study was conducted according to Experiment 4.
＜実験結果＞
１．ナトリウム濃度測定の結果を表１１に示す。
(1) コントロールにおいて，投与後１時間において，血漿中ナトリウム濃度が0.86%まであがり，投与後２時間においては，0.72%とやや下がった値であったが，投与前よりも高い値に落ち着いていた。
(2) 試作例２６では，投与後１時間において血漿中ナトリウム濃度が0.81%，投与後２時間で0.74%と，コントロールと比較してやや低い値であった。
(3) 試作例２７では，投与後１時間において血漿中ナトリウム濃度が0.76%，投与後２時間で0.67%と，コントロールと比較して低下していた。
(4) 試作例２８では，投与後１時間において血漿中ナトリウム濃度が0.78%，投与後２時間で0.67%と，コントロールと比較して低下していた。
<Experimental result>
1. The results of sodium concentration measurement are shown in Table 11.
(1) In the control, the plasma sodium concentration increased to 0.86% at 1 hour after administration, and decreased slightly to 0.72% at 2 hours after administration, but remained at a higher value than before administration. It was.
(2) In Prototype 26, the plasma sodium concentration was 0.81% 1 hour after administration and 0.74% 2 hours after administration, which was slightly lower than the control.
(3) In Prototype 27, the plasma sodium concentration was 0.76% 1 hour after administration, and 0.67% 2 hours after administration, a decrease compared to the control.
(4) In Prototype 28, the plasma sodium concentration was 0.78% 1 hour after administration and 0.67% 2 hours after administration, which was lower than the control.
３．カリウム濃度測定結果を表１２に示す。
(1) コントロールにおいて，投与後１時間において，血漿中ナトリウム濃度が230ppmまであがり，投与後２時間においては，180ppmとやや下がった値であったが，投与前よりも高い値に落ち着いていた。
(2) 試作例２６では，投与後１時間で165ppm，投与後２時間で240ppmと経時的に増加していった。
(3) 試作例２７では，投与後１時間で200ppm，投与後２時間で200ppmと，コントロールと比較すると，より低い傾向であった。
(4) 試作例２８では，投与後１時間で190ppm，投与後２時間で210ppmと，経時的に増加していた。
3. The results of measuring the potassium concentration are shown in Table 12.
(1) In the control, the sodium concentration in plasma increased to 230 ppm at 1 hour after administration, and the value dropped slightly to 180 ppm at 2 hours after administration, but remained at a higher value than before administration.
(2) In Prototype 26, it increased over time to 165 ppm 1 hour after administration and 240 ppm 2 hours after administration.
(3) In Prototype 27, 200 ppm at 1 hour after administration and 200 ppm at 2 hours after administration, which was lower than the control.
(4) In Prototype 28, it increased over time to 190 ppm 1 hour after administration and 210 ppm 2 hours after administration.
実施例より本発明のナトリウム排出用食品組成物は，アルギン酸塩（ナトリウム塩を除く）を有効成分とする排塩組成物であり，特に好ましい構成として，アルギン酸アンモニウム塩を20〜70%，アルギン酸カルシウム塩を20〜70%の重量比率で含むとともに，賦形剤として野菜パウダー又はハーブパウダーを用いる構成とすることが考えられる。これにより，優れたナトリウム吸着能を発揮するとともに，血中カリウム濃度の上昇を防ぐことが可能となると考えられる。 From the examples, the food composition for sodium discharge of the present invention is a waste salt composition containing an alginate (excluding a sodium salt) as an active ingredient. As a particularly preferred constitution, 20 to 70% ammonium alginate is composed of calcium alginate. It is conceivable that the composition contains salt in a weight ratio of 20 to 70% and uses vegetable powder or herb powder as an excipient. As a result, it is considered that an excellent sodium adsorption ability can be exhibited and an increase in blood potassium concentration can be prevented.
＜＜実験７．飲料を用いた検討＞＞
アルギン酸アンモニウムとアルギン酸カルシウムを用いた試作例を飲料に用いて，どの程度の塩分濃度抑制がみられるかを調べるため，検討を行った。
<< Experiment 7. Examination using beverages >>
A trial example using ammonium alginate and calcium alginate was used to examine how much salt concentration suppression was observed in beverages.
＜実験方法＞
１．実験１と同様の手法により行った。
２．なお，用いる試作例については，飲料中における最終濃度を50mg/mLとした（原料飲料中のサンプル含有比率としては，およそ5%程度）。
<Experiment method>
1. The same method as in Experiment 1 was performed.
2. For the prototype to be used, the final concentration in the beverage was 50 mg / mL (the sample content ratio in the raw beverage was about 5%).
＜実験結果＞
１．結果を表１３ならびに表１４に示す。表中，NCはネガティブコントロールとして飲料原液を，PCはポジティブコントロールとして飲料原液に塩化ナトリウムを1%（w/v）添加したものを示す。また，抑制率については，NCと比較した場合のPCにおけるナトリウム濃度増加分を100%として，これをどれだけ抑制したの観点から，下記式（数２）に従い，算出した。
<Experimental result>
1. The results are shown in Table 13 and Table 14. In the table, NC represents the beverage stock solution as a negative control, and PC represents 1% (w / v) sodium chloride added to the beverage stock solution as a positive control. In addition, the inhibition rate was calculated according to the following formula (Equation 2) from the viewpoint of how much the sodium concentration increase in PC when compared with NC was 100%.
(1) 全ての検討において，試作例の添加により塩分濃度が低下していた。
(2) また，一部例外はあるものの，検討を行ったほとんどにおいても，アルギン酸アンモニウムの比率が増加するにつれ，塩分濃度が低下する傾向であった。
(3) 抑制率を見てみると，全ての飲料で，少なくとも30%を越える抑制率を示すサンプルが確認された。また，No３，６，９，１２，１３，１５においては抑制率が40%を越え優れた抑制効果を示すサンプルが確認された。さらにNo1，１２においては抑制率が50%以上と，顕著な抑制効果を示すサンプルが確認された。
(1) In all studies, the salt concentration decreased due to the addition of the prototype.
(2) In addition, with some exceptions, most of the studies tended to decrease the salinity as the proportion of ammonium alginate increased.
(3) Looking at the inhibition rate, samples showing inhibition rates exceeding 30% were confirmed for all beverages. In Nos. 3, 6, 9, 12, 13, and 15, samples with an inhibition rate exceeding 40% and showing an excellent inhibition effect were confirmed. Furthermore, in No1 and No.12, the suppression rate was 50% or more, and the sample which shows a remarkable suppression effect was confirmed.
２．カリウム濃度の測定結果を表１５に示す。
(1) もともとカリウム含有量が極めて低い飲料（No9，10，11，14）については，サンプルの添加により，カリウム濃度がわずかではあるが増加ないしはほぼ同じ濃度を維持していた。
(2) 一方，カリウム含有量が比較的高いと思われる飲料については，サンプルの添加により，カリウム濃度が減少していた。すなわち，これらの飲料については，ナトリウムの抑制のみならず，カリウムについても抑制効果があることが分かった。
2. Table 15 shows the measurement results of the potassium concentration.
(1) For beverages with extremely low potassium content (Nos. 9, 10, 11, and 14), the potassium concentration was slightly increased or maintained at the same level by adding samples.
(2) On the other hand, for beverages that appear to have a relatively high potassium content, the potassium concentration decreased with the addition of the sample. In other words, these beverages were found to have an inhibitory effect not only on sodium but also on potassium.
３．一部の飲料において，塩化ナトリウムとサンプル（被験物質）の添加の順番を変えて検討した結果を表１６，表１７に示す。いずれの飲料においても，添加の順番により，塩分濃度ならびにカリウム濃度の結果に変化はなかった。 3. Tables 16 and 17 show the results obtained by changing the order of adding sodium chloride and the sample (test substance) in some beverages. In all beverages, the results of salt concentration and potassium concentration did not change with the order of addition.
Claims (16)
A food composition for preventing renal dysfunction according to any one of claims 1 to 15, wherein the food composition is used for the purpose of preventing renal dysfunction.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017130296 | 2017-07-03 | ||
| JP2017130296 | 2017-07-03 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018126457A Division JP2019013221A (en) | 2017-07-03 | 2018-07-03 | Food composition aiming at sodium excretion |
| JP2018189779A Division JP2019013244A (en) | 2017-07-03 | 2018-10-05 | Food composition for sodium discharge |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019013220A true JP2019013220A (en) | 2019-01-31 |
| JP6497764B2 JP6497764B2 (en) | 2019-04-10 |
Family
ID=65356227
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018125691A Active JP6497764B2 (en) | 2017-07-03 | 2018-07-02 | Food composition for sodium discharge |
| JP2018126457A Pending JP2019013221A (en) | 2017-07-03 | 2018-07-03 | Food composition aiming at sodium excretion |
| JP2018189779A Pending JP2019013244A (en) | 2017-07-03 | 2018-10-05 | Food composition for sodium discharge |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018126457A Pending JP2019013221A (en) | 2017-07-03 | 2018-07-03 | Food composition aiming at sodium excretion |
| JP2018189779A Pending JP2019013244A (en) | 2017-07-03 | 2018-10-05 | Food composition for sodium discharge |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JP6497764B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113905619A (en) * | 2019-05-28 | 2022-01-07 | 萄易医疗株式会社 | Sodium-emitting particles |
| JP7369819B2 (en) | 2022-03-31 | 2023-10-26 | 博也 古田 | Method for producing sodium-adsorbing solid material and food composition for salt removal containing the solid material |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6497764B2 (en) * | 2017-07-03 | 2019-04-10 | トイメディカル株式会社 | Food composition for sodium discharge |
| WO2021212006A1 (en) * | 2020-04-16 | 2021-10-21 | No-Dium Llc | Ion capture composition for ingestion |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5934853A (en) * | 1982-08-20 | 1984-02-25 | Horiuchi Itarou Shoten:Kk | Food additive |
| JPS60130523A (en) * | 1983-12-16 | 1985-07-12 | Yamasa Shoyu Co Ltd | Medical food additive and food containing the same |
| JPH11510499A (en) * | 1995-08-03 | 1999-09-14 | ディートル、ハンス | Calcium-containing composition for intestinal phosphate binding and method of making same |
| JP2009057343A (en) * | 2007-09-03 | 2009-03-19 | Kikkoman Corp | Sodium absorption inhibition composition |
| JP2018126457A (en) * | 2017-02-10 | 2018-08-16 | サミー株式会社 | Reel type game machine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826691A (en) * | 1987-08-03 | 1989-05-02 | Berkley, Inc. | Carrier for fish attractant |
| JP5561884B1 (en) * | 2013-07-24 | 2014-07-30 | 伊那食品工業株式会社 | DRY COMPOSITION AND FOOD CONTAINING THE SAME |
| CN103719896A (en) * | 2013-11-30 | 2014-04-16 | 青岛海之林生物科技开发有限公司 | Alginate additive used for sausage meat products |
| JP6497764B2 (en) * | 2017-07-03 | 2019-04-10 | トイメディカル株式会社 | Food composition for sodium discharge |
-
2018
- 2018-07-02 JP JP2018125691A patent/JP6497764B2/en active Active
- 2018-07-03 JP JP2018126457A patent/JP2019013221A/en active Pending
- 2018-10-05 JP JP2018189779A patent/JP2019013244A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5934853A (en) * | 1982-08-20 | 1984-02-25 | Horiuchi Itarou Shoten:Kk | Food additive |
| JPS60130523A (en) * | 1983-12-16 | 1985-07-12 | Yamasa Shoyu Co Ltd | Medical food additive and food containing the same |
| JPH11510499A (en) * | 1995-08-03 | 1999-09-14 | ディートル、ハンス | Calcium-containing composition for intestinal phosphate binding and method of making same |
| JP2009057343A (en) * | 2007-09-03 | 2009-03-19 | Kikkoman Corp | Sodium absorption inhibition composition |
| JP2018126457A (en) * | 2017-02-10 | 2018-08-16 | サミー株式会社 | Reel type game machine |
Non-Patent Citations (8)
| Title |
|---|
| FOOD STYLE21, 2007, VOL.11, NO.8, PP.62,63, JPN6018032570, ISSN: 0003972601 * |
| フードリサーチ, 1996, VOL.111, PP.76-79, JPN6018032559, ISSN: 0003972595 * |
| 日本家政学会誌, 1988, VOL.39, NO.3, PP.187-195, JPN6018032561, ISSN: 0003972596 * |
| 朝倉富子, 公益財団法人ソルト・サイエンス研究財団，平成２２年度助成研究報告集 II 医学 食品科学編,, JPN6018032572, ISSN: 0003972602 * |
| 株式会社キミカ, アルギン酸カリウム, [ONLINE], 2017.06.13, [2018.08.16 検索], <URL:HTTPS://WWW.KIMICA, JPN6018032566, ISSN: 0003972599 * |
| 株式会社キミカ, アルギン酸カルシウム, [ONLINE], 2017.05.31, [2018.08.16 検索], <URL:HTTPS://WWW.KIMI, JPN6018032569, ISSN: 0003972600 * |
| 繊維と工業, 2009, VOL.65, NO.12, PP.444-448, JPN6018032565, ISSN: 0003972598 * |
| 近田浩之, 日本栄養・食糧学会大会講演要旨集, 2008, VOL.62. P.188, 2F-14P, JPN6018032563, ISSN: 0003972597 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113905619A (en) * | 2019-05-28 | 2022-01-07 | 萄易医疗株式会社 | Sodium-emitting particles |
| JP7369819B2 (en) | 2022-03-31 | 2023-10-26 | 博也 古田 | Method for producing sodium-adsorbing solid material and food composition for salt removal containing the solid material |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6497764B2 (en) | 2019-04-10 |
| JP2019013244A (en) | 2019-01-31 |
| JP2019013221A (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6497764B2 (en) | Food composition for sodium discharge | |
| JP6265500B2 (en) | Dry eye prevention and treatment | |
| JP5207611B2 (en) | Saccharification inhibitor | |
| Contreras | Anticariogenic properties and effects on periodontal structures of Stevia rebaudiana Bertoni. Narrative review | |
| AU2011318300B2 (en) | Metal ion nanoclusters | |
| JP4264105B2 (en) | Isosorbide-containing jelly preparation | |
| KR20200071063A (en) | Sweetener and taste masking compositions, products and uses thereof | |
| JPWO2014010656A1 (en) | Excellent promoter for lowering blood alcohol levels | |
| JPWO2005074961A1 (en) | Body fat regulator | |
| KR20050078663A (en) | Food improving blood flow | |
| JP2008189638A (en) | Suppressor of blood sugar level increase | |
| JPH11180888A (en) | Antimicrobial, infection preventive and food product against helicobacter pylori bacteria | |
| JP2005187405A (en) | Uric acid value inhibitor and purine body adsorbent | |
| ES2759797T3 (en) | Mixtures of substances | |
| JP5543656B1 (en) | Composition containing useful ingredients in turmeric | |
| JP2006335752A (en) | Aldose reduction enzyme inhibitor | |
| KR101444875B1 (en) | Beverage composition comprising hibiscus extract and l-carnitine with improved sensory property and stability | |
| JP2005298429A (en) | Vascular endothelial type nitric oxide synthase activity promoter | |
| JP2006306747A (en) | Agent containing tussilago farfara extract for preventing or improving life cycle-related diseases | |
| EP3960201A1 (en) | Composition for promoting glp-1 secretion | |
| JP2017119641A (en) | Method for testing possibility of nash and oral composition | |
| KR20170076496A (en) | Improved solubility and safe amorphous curcuminoid solid dispersion composition and manufacturing method thereof | |
| JP2011079789A (en) | Angiotensin i converting enzyme inhibitor | |
| JP5186145B2 (en) | Pharmaceutical or food composition for preventing or treating hyperuricemia or diseases caused thereby | |
| JP7300446B2 (en) | exocrine stimulant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190115 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190206 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190307 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190307 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6497764 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |